AGP Executive Report
Last update: 10 hours agoCancer Care: The European Medicines Agency’s medicines committee recommended Zybrivo with chemotherapy as a first-line option for adults with advanced non-squamous lung cancer; European Commission approval is still pending. The committee also backed belzutifan plus lenvatinib for some adults with advanced kidney cancer after prior treatment, with a final decision expected within two months. Rare Conditions: The European Commission approved Zeydovio for adults with short bowel syndrome, marking the first major treatment advance for the condition in Europe in more than a decade. Child Health: EU advisers recommended expanding Merck’s RSV prevention treatment to cover high-risk children through a second season. A final decision is expected within two months and would include Liechtenstein.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.